BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E
95 results:

  • 1. Risk of cancer in relatives of patients with myelodysplastic neoplasia and acute leukemias.
    Nitschke NJ; Rostgaard K; Andersen MK; Hjalgrim H; Grønbæk K
    Cancer Epidemiol; 2024 Feb; 88():102523. PubMed ID: 38198910
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. SPI1-mediated MIR222HG transcription promotes proneural-to-mesenchymal transition of glioma stem cells and immunosuppressive polarization of macrophages.
    Fan Y; Gao Z; Xu J; Wang H; Guo Q; Li B; Li M; Xu H; Qi Y; Zhao S; Qiu W; Pan Z; Wang Q; Xue H; Zhao R; Guo X; Li G
    Theranostics; 2023; 13(10):3310-3329. PubMed ID: 37351164
    [No Abstract]    [Full Text] [Related]  

  • 3. Multi-Targeting Neuroprotective Effects of
    Sharma H; Kim DY; Shim KH; Sharma N; An SSA
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175851
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach.
    Gordon S; Chan DLH; Bernard EJ; Eslick ME; Willowson KP; Roach PJ; Engel AF; Maher R; Clarke SJ; Agarwal V; Yasmin L; De Silva M; Mascall S; Conner A; Nevell D; Pavlakis N; Bailey DL
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7717-7728. PubMed ID: 37004598
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Breast metastasis in high-grade endometrial stromal sarcoma (HG-ESS) with BCOR rearrangement: a case report of a novel metastatic site.
    Fong A; Offman S
    Diagn Pathol; 2023 Mar; 18(1):34. PubMed ID: 36864468
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
    Makishima H; Saiki R; Nannya Y; Korotev S; Gurnari C; Takeda J; Momozawa Y; Best S; Krishnamurthy P; Yoshizato T; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Nagata Y; Kakiuchi N; Onizuka M; Chiba K; Tanaka H; Kon A; Ochi Y; Nakagawa MM; Okuda R; Mori T; Yoda A; Itonaga H; Miyazaki Y; Sanada M; Ishikawa T; Chiba S; Tsurumi H; Kasahara S; Müller-Tidow C; Takaori-Kondo A; Ohyashiki K; Kiguchi T; Matsuda F; Jansen JH; Polprasert C; Blombery P; Kamatani Y; Miyano S; Malcovati L; Haferlach T; Kubo M; Cazzola M; Kulasekararaj AG; Godley LA; Maciejewski JP; Ogawa S
    Blood; 2023 Feb; 141(5):534-549. PubMed ID: 36322930
    [TBL] [Abstract] [Full Text] [Related]  

  • 7.
    Tan MA; Ishikawa H; An SSA
    Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235616
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
    Farheen S; Ahmed SP; Mariyath P M M; Kausar T; Hoda MF; Arif SH; Nayeem SM; Ali A; Chosdol K; Shahi MH
    J Biochem Mol Toxicol; 2023 Feb; 37(2):e23241. PubMed ID: 36205257
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. germ line predisposition variants occur in myelodysplastic syndrome patients of all ages.
    Feurstein S; Trottier AM; Estrada-Merly N; Pozsgai M; McNeely K; Drazer MW; Ruhle B; Sadera K; Koppayi AL; Scott BL; Oran B; Nishihori T; Agrawal V; Saad A; Lindsley RC; Nakamura R; Kim S; Hu Z; Sobecks R; Spellman S; Saber W; Godley LA
    Blood; 2022 Dec; 140(24):2533-2548. PubMed ID: 35969835
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Temozolomide duration and secondary hematological neoplasms: A literature review and implications for patients with neuroendocrine neoplasms.
    Park R; Amin M; Trikalinos NA
    J Neuroendocrinol; 2022 Jul; 34(7):e13178. PubMed ID: 35854663
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The efficacy, toxicity and survival of salvage retreatment PRRT with
    Sitani K; Parghane R; Talole S; Basu S
    Br J Radiol; 2022 Sep; 95(1137):20210896. PubMed ID: 35816545
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.
    Badar T; Chlon T
    Curr Hematol Malig Rep; 2022 Oct; 17(5):113-120. PubMed ID: 35781188
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Long-term survival and toxicity in patients with neuroendocrine tumors treated with
    Kennedy KR; Turner JH; MacDonald WBG; Claringbold PG; Boardman G; Ransom DT
    Cancer; 2022 Jun; 128(11):2182-2192. PubMed ID: 35363879
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Immunodepletion of mdsC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in mds and melanoma.
    Cheng P; Chen X; Dalton R; Calescibetta A; So T; Gilvary D; Ward G; Smith V; Eckard S; Fox JA; Guenot J; Markowitz J; Cleveland JL; Wright KL; List AF; Wei S; Eksioglu EA
    Mol Ther; 2022 Jun; 30(6):2315-2326. PubMed ID: 35150889
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia.
    Spitzer B; Rutherford KD; Gundem G; McGovern EM; Millard NE; Arango Ossa JE; Cheung IY; Gao T; Levine MF; Zhang Y; Medina-Martínez JS; Feng Y; Ptashkin RN; Bolton KL; Farnoud N; Zhou Y; Patel MA; Asimomitis G; Cobbs CC; Mohibullah N; Huberman KH; Arcilla ME; Kushner BH; Modak S; Kung AL; Zehir A; Levine RL; Armstrong SA; Cheung NKV; Papaemmanuil E
    Clin Cancer Res; 2022 Apr; 28(8):1614-1627. PubMed ID: 35078859
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Myeloid Toxicity of Radionuclide Cancer Therapy.
    Kesavan M; Turner JH
    Cancer Biother Radiopharm; 2022 Apr; 37(3):164-172. PubMed ID: 34871036
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes.
    Sahoo SS; Pastor VB; Goodings C; Voss RK; Kozyra EJ; Szvetnik A; Noellke P; Dworzak M; Starý J; Locatelli F; Masetti R; Schmugge M; De Moerloose B; Catala A; Kállay K; Turkiewicz D; Hasle H; Buechner J; Jahnukainen K; Ussowicz M; Polychronopoulou S; Smith OP; Fabri O; Barzilai S; de Haas V; Baumann I; Schwarz-Furlan S; ; Niewisch MR; Sauer MG; Burkhardt B; Lang P; Bader P; Beier R; Müller I; Albert MH; Meisel R; Schulz A; Cario G; Panda PK; Wehrle J; Hirabayashi S; Derecka M; Durruthy-Durruthy R; Göhring G; Yoshimi-Noellke A; Ku M; Lebrecht D; Erlacher M; Flotho C; Strahm B; Niemeyer CM; Wlodarski MW
    Nat Med; 2021 Oct; 27(10):1806-1817. PubMed ID: 34621053
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. In silico identification of natural product inhibitors against Octamer-binding transcription factor 4 (Oct4) to impede the mechanism of glioma stem cells.
    Nayak C; Singh SK
    PLoS One; 2021; 16(10):e0255803. PubMed ID: 34613998
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Screening of
    Chandel S; Singh R; Gautam A; Ravichandiran V
    J Biomol Struct Dyn; 2022; 40(23):12827-12840. PubMed ID: 34569452
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
    Morra A; Escala-Garcia M; Beesley J; Keeman R; Canisius S; Ahearn TU; Andrulis IL; Anton-Culver H; Arndt V; Auer PL; Augustinsson A; Beane Freeman LE; Becher H; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brenner H; Brüning T; Buys SS; Caan B; Campa D; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Cheng TD; Clarke CL; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Dörk T; Dossus L; Dunning AM; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Eriksson M; Evans DG; Fasching PA; Flyger H; Fritschi L; Gago-Dominguez M; García-Sáenz JA; Giles GG; Grip M; Guénel P; Gündert M; Hahnen E; Haiman CA; Håkansson N; Hall P; Hamann U; Hart SN; Hartikainen JM; Hartmann A; He W; Hooning MJ; Hoppe R; Hopper JL; Howell A; Hunter DJ; ; ; Jager A; Jakubowska A; Janni W; John EM; Jung AY; Kaaks R; Keupers M; Kitahara CM; Koutros S; Kraft P; Kristensen VN; Kurian AW; Lacey JV; Lambrechts D; Le Marchand L; Lindblom A; Linet M; Luben RN; Lubiński J; Lush M; Mannermaa A; Manoochehri M; Margolin S; Martens JWM; Martinez ME; Mavroudis D; Michailidou K; Milne RL; Mulligan AM; Muranen TA; Nevanlinna H; Newman WG; Nielsen SF; Nordestgaard BG; Olshan AF; Olsson H; Orr N; Park-Simon TW; Patel AV; Peissel B; Peterlongo P; Plaseska-Karanfilska D; Prajzendanc K; Prentice R; Presneau N; Rack B; Rennert G; Rennert HS; Rhenius V; Romero A; Roylance R; Ruebner M; Saloustros E; Sawyer EJ; Schmutzler RK; Schneeweiss A; Scott C; Shah M; Smichkoska S; Southey MC; Stone J; Surowy H; Swerdlow AJ; Tamimi RM; Tapper WJ; Teras LR; Terry MB; Tollenaar RAEM; Tomlinson I; Troester MA; Truong T; Vachon CM; Wang Q; Hurson AN; Winqvist R; Wolk A; Ziogas A; Brauch H; García-Closas M; Pharoah PDP; Easton DF; Chenevix-Trench G; Schmidt MK
    Breast Cancer Res; 2021 Aug; 23(1):86. PubMed ID: 34407845
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.